Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vebreltinib + Platinum-Doublet Chemotherapy in First-Line Advanced NSCLC
NCT07549061Phase 2Not yet recruiting
- Sponsor
- Shanghai Chest Hospital
- Start
- Mar 2026
- Primary completion
- May 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vebreltinib in non-small cell lung cancer (NSCLC), sponsored by Shanghai Chest Hospital. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
vebreltinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07549061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07549061.